Apurano Pharmaceuticals GmbH
- Address
- Birkerfeld 12, Lochham
Sponsor Overview
Specializations
Chronic Pain and Neuropathic Pain
Apurano Pharmaceuticals GmbH focuses on clinical research in persistent pain conditions, with particular attention to chronic back pain and pain linked to peripheral neuropathy and central neuropathy.
- Chronic back pain
- Traumatic peripheral neuropathy
- Post-operative peripheral neuropathy
- Central neuropathic pain
The sponsor also investigates pain associated with diabetic polyneuropathy, reflecting a strong therapeutic interest in difficult-to-treat nerve-related pain syndromes.
Peripheral Nervous System Disorders
Its research portfolio includes conditions arising from injury or disease affecting the peripheral nervous system, especially pain syndromes following surgery or trauma.
- Peripheral neuropathy
- Trauma-related nerve pain
- Post-surgical neuropathic pain
These studies indicate sustained interest in therapies targeting nerve dysfunction and the management of long-term sensory pain.
Diabetic Neuropathy
Apurano Pharmaceuticals GmbH is active in research addressing pain due to diabetic polyneuropathy, a major complication of diabetes mellitus involving chronic nerve damage and pain.
- Diabetic polyneuropathy
- Neuropathic pain in diabetes
This area highlights interest in symptom control for metabolic nerve disease and its impact on daily functioning.
Borderline Personality Disorder
The sponsor also supports clinical research in borderline personality disorder, extending its portfolio beyond pain medicine into psychiatric care.
- Borderline personality disorder
- Psychiatric symptom assessment
This area of interest centers on the clinical burden of mood instability, interpersonal difficulties, and related symptom domains.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of AP707 in Patients with Borderline Personality Disorder: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial |  Germany | Not Yet Recruiting |
| Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain |  Austria Germany | Not Recruiting |
| Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis | Austria Germany | Not Recruiting |
| Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy | Austria Germany | Not Recruiting |
| Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy | Austria Germany | Not Recruiting |
Data & Insights
This sponsor works with 25 molecules, of which 8 are not being studied by other sponsors.
This sponsor has worked with 65 sites across their trial portfolio.
Therapeutic Focus
- 1.Pathological Conditions, Signs and Symptoms4 trials91 other sponsors
- 2.Mental Disorders1 trial150 other sponsors
Partnered Research Centres
65 centres- Address
- Hessstrasse 22, Maxvorstadt, 80799 Munich
- Address
- Am Tannwald 1-3, 79215 Elzach
- Address
- Buerkle De La Camp-Platz 1, Wiemelhausen, 44789 Bochum
- Address
- Geschwister-Schoenert-Strasse 1, Kriegshaber, 86156 Augsburg
- Address
- Schnarrenbergstrasse 95, 72076 Tübingen
- Address
- Grossenbaumer Allee 250, Buchholz, 47249 Duisburg
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Apurano Pharmaceuticals GmbH.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.